Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.

T. Ohnoshi, S. Hiraki, N. Ueda, M. Fujii, K. Machida, H. Ueoka, S. Kawahara, A. Kozuka, Katsuyuki Kiura, T. Moritaka

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

Original languageEnglish
Pages (from-to)357-361
Number of pages5
JournalActa Medica Okayama
Volume45
Issue number5
Publication statusPublished - Oct 1991

Fingerprint

Vindesine
Ifosfamide
Non-Small Cell Lung Carcinoma
Cisplatin
Cells
Drug Combinations
Hydration
Toxicity
Adenocarcinoma
Clinical Trials
Survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ohnoshi, T., Hiraki, S., Ueda, N., Fujii, M., Machida, K., Ueoka, H., ... Moritaka, T. (1991). Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. Acta Medica Okayama, 45(5), 357-361.

Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. / Ohnoshi, T.; Hiraki, S.; Ueda, N.; Fujii, M.; Machida, K.; Ueoka, H.; Kawahara, S.; Kozuka, A.; Kiura, Katsuyuki; Moritaka, T.

In: Acta Medica Okayama, Vol. 45, No. 5, 10.1991, p. 357-361.

Research output: Contribution to journalArticle

Ohnoshi, T, Hiraki, S, Ueda, N, Fujii, M, Machida, K, Ueoka, H, Kawahara, S, Kozuka, A, Kiura, K & Moritaka, T 1991, 'Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.', Acta Medica Okayama, vol. 45, no. 5, pp. 357-361.
Ohnoshi T, Hiraki S, Ueda N, Fujii M, Machida K, Ueoka H et al. Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. Acta Medica Okayama. 1991 Oct;45(5):357-361.
Ohnoshi, T. ; Hiraki, S. ; Ueda, N. ; Fujii, M. ; Machida, K. ; Ueoka, H. ; Kawahara, S. ; Kozuka, A. ; Kiura, Katsuyuki ; Moritaka, T. / Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. In: Acta Medica Okayama. 1991 ; Vol. 45, No. 5. pp. 357-361.
@article{bf98f0e56ec04bb4ba2bb26704ba6e6f,
title = "Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.",
abstract = "Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63{\%} (95{\%} confidence limit: 45{\%} to 81{\%}). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.",
author = "T. Ohnoshi and S. Hiraki and N. Ueda and M. Fujii and K. Machida and H. Ueoka and S. Kawahara and A. Kozuka and Katsuyuki Kiura and T. Moritaka",
year = "1991",
month = "10",
language = "English",
volume = "45",
pages = "357--361",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.

AU - Ohnoshi, T.

AU - Hiraki, S.

AU - Ueda, N.

AU - Fujii, M.

AU - Machida, K.

AU - Ueoka, H.

AU - Kawahara, S.

AU - Kozuka, A.

AU - Kiura, Katsuyuki

AU - Moritaka, T.

PY - 1991/10

Y1 - 1991/10

N2 - Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

AB - Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0026231091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026231091&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 357

EP - 361

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -